SEZI Share Price Performance
SEK 4.55
-0.33 (-6.76%)
52.1% undervalued intrinsic discount
SEK 9.50
Fair Value
Price SEK 4.55
AnalystConsensusTarget SEK 9.50
Fair ValueSEK 9.50
Share Pricen/a
Narrative Update • May 15
Senzime AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
SEZI Community Narratives
AN
Fair Value
·Fair Value SEK 9.5 52.1% undervalued intrinsic discount
US And European Guidelines Will Expand Neuromuscular Monitoring Adoption Worldwide
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US And European Guidelines Will Expand Neuromuscular Monitoring Adoption Worldwide
Hospital rules in the U.S. and Europe increasingly push doctors to use objective neuromuscular monitoring during surgery, which could speed up adoption of Senzime’s TetraGraph system and its repeat-use sensors. The upside hinges on winning new patient groups and expanding beyond the U.S., but tariffs, currency swings, and reliance on a single product line could derail the story.Read more
AN
SEK 9.5
52.1% undervalued intrinsic discount
Fair Value
Profit Margin
10.3%
Future PE
58.25x
Price in 2029
SEK 11.22
Trending Discussion
Recently Updated Narratives
AN
SEZI: Expanded US Hospital Access And Connectivity Will Support Future Earnings Power
Fair Value: SEK 9.5 52.1% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Senzime AB (publ) Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 16, 2026
- -0.80
- 32.74%
- -120.73%
- 2.6%
About SEZI
- Founded
- 1999
- Employees
- 59
- CEO
- WebsiteView website
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz Analyzer and OnZurf Probe. The company has a strategic connectivity and licensing agreement with Masimo to develop, manufacture, market, and distribute products that can connect to the Masimo Root patient monitoring system; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system. Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.
Recent SEZI News & Updates
Narrative Update • Apr 25
